- Home
- HERZ vs NRSN Comparison
HERZ vs NRSN Comparison
Compare HERZ & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | NRSN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Israel |
| Employees | N/A | 16 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 26.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HERZ | NRSN |
|---|---|---|
| Price | $18.73 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 3.8K | ★ 129.0K |
| Earning Date | N/A | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $0.63 |
| 52 Week High | $19.30 | $2.60 |
Technical Indicators
Market Signals| Indicator | HERZ | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 51.24 |
| Support Level | $17.42 | $0.67 |
| Resistance Level | $19.08 | $0.86 |
| Average True Range (ATR) | 0.78 | 0.07 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 41.91 | 49.14 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.